Calumet delivered in-line Q4 2024 results, with management's asset sales and cash generation efforts creating a favorable buying opportunity. Specialty EBITDA is projected to improve to the low $200 million range in 2025, driven by stronger Gulf Coast 2-1-1 spreads and operational efficiencies. The partial sale of Performance Brands for $110 million will be offset by operational efficiencies, maintaining EBITDA levels over the next two years.
Calumet, Inc. (NASDAQ:CLMT ) Q4 2024 Earnings Conference Call February 28, 2025 9:00 AM ET Company Participants John Kompa - Investor Relations Todd Borgmann - Chief Executive Officer David Lunin - Executive Vice President & Chief Financial Officer Bruce Fleming - Executive Vice President, Montana Renewables & Corporate Development Scott Obermeier - Executive Vice President, Specialists Conference Call Participants Roger Read - Wells Fargo Jason Gabelman - TD Cowen Neil Mehta - Goldman Sachs Gregg Brody - Bank of America Operator Good morning, and welcome to the Calumet, Inc. Fourth Quarter and Full Year 2024 Results Conference Call. All participants will be in listen-only mode.
WICHITA, Kas., Feb. 28, 2025 /PRNewswire/ -- Lubrication Engineers, Inc. ("LE"), a leading developer and manufacturer of high-performance industrial lubricants and asset reliability solutions, today announced that it has entered into a definitive agreement to acquire the industrial brands and products of Royal Purple ("RPI"), a leading provider of specialty synthetic performance lubricants and greases for diversified industrial applications.
Calumet, Inc. (CLMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Calumet, Inc. (CLMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Calumet, Inc. (CLMT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Calumet Specialty Products has transformed from difficult times to a valuable long-term investment, driven by superb execution, patience, and strategic asset management. Management announced a special analyst conference detailing an $800 million DOE loan at zero percent interest for four years, with significant debt reduction benefits. MRL production capacity will increase significantly through Phase I and Phase II expansions, promising substantial profit lifts and cost reductions.
INDIANAPOLIS , Jan. 14, 2025 /PRNewswire/ -- Calumet, Inc. (NASDAQ: CLMT) (the "Company" or "Calumet") today announced that its wholly owned subsidiaries, Calumet Specialty Products Partners, L.P. (the "Partnership") and Calumet Finance Corp. (together with the Partnership, the "Issuers"), priced their private placement (the "Offering") under Rule 144A and Regulation S under the Securities Act of 1933, as amended (the "Securities Act"), of $100 million in aggregate principal amount of 9.75% Senior Notes due 2028 (the "New Notes").
INDIANAPOLIS , Jan. 14, 2025 /PRNewswire/ -- Calumet, Inc. (NASDAQ: CLMT) (the "Company" or "Calumet") today announced that, subject to market conditions, its wholly owned subsidiaries, Calumet Specialty Products Partners, L.P. (the "Partnership") and Calumet Finance Corp. (together with the Partnership, the "Issuers"), intend to offer (the "Offering") for sale to eligible purchasers in a private placement under Rule 144A and Regulation S under the Securities Act of 1933, as amended (the "Securities Act"), $100 million in aggregate principal amount of 9.75% Senior Notes due 2028 (the "New Notes").
INDIANAPOLIS , Jan. 14, 2025 /PRNewswire/ -- Calumet, Inc. (NASDAQ: CLMT) (the "Company" or "Calumet") today announced that the Company has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") establishing an at-the-market equity offering program (the "ATM Program") under which it may issue and sell, from time to time, shares of its common stock having an aggregate gross sales price of up to $65 million (the "Offered Shares"). Calumet intends to use the net proceeds from the ATM Program for general corporate purposes, which may include, among other things, repayment of indebtedness, working capital and capital expenditures.